General information, not legal or regulatory advice. Confirm current agency, holder, import, and post-market rules with qualified advisers. We do not invent Pure Global, freelancer, or competitor rates. Where a card is mentioned, only the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub applies. No unpublished client. No PHI. Always bioaccess®.
If you searched Brazil RA consultant medical device, ANVISA regulatory consultant, or Brazil regulatory affairs consultant medical device, you were looking for advice that is often mistaken for the BRH / detentor / ANVISA operator stack. This page owns that search intent: BRH stack vs freelance advice. It does not name freelancers. No PHI. Always bioaccess®.
The leak: a consultant who drafts ANVISA dossiers, advises on classification, or coaches RDC language is still not the ethics calendar + IOR + site network + inspection-ready ops stack — and for commercial devices is still not the Brazilian Registration Holder (BRH / detentor) named on the certificate. bioaccess® is the LATAM FIH CRO and local RA / IOR operator that owns that stack.
What the search usually means vs what execution requires
- Search intent often means: someone who “knows ANVISA” for cadastro/registro, BGMP awareness, or clinical submission coaching under RDC 837/2023.
- Execution requires: Portuguese dossier discipline; CEP ethics capped on live Brazil hubs; ANVISA trial authorization where applicable; investigational or commercial import entity; sites that enroll; or, for commercial SKUs, BRH / detentor on the certificate plus IOR on the entry.
- A freelance ANVISA RA retainer usually covers: gap assessment, dossier outline, and meeting prep — not BRH ownership and not ISO 14155 monitoring.
- Do not collapse: INMETRO / ANATEL homologation, BGMP audit pass-through, and BRH into one “Brazil RA” invoice line without reading the holder hub.
ANVISA / BRH stack: trial vs commercial
Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000 on that hub. Trial authorization and later market registration are separate workstreams. We will not invent a new ANVISA clock on this page.
Commercial BRH / IOR: Brazil ANVISA Registration Holder / IOR (BRH / Detentor). Locked public card: LATAM Launch Subscription USD 7,500/year all-in for the first device family on market-access and LATAM Registration Holder and IOR. Brazil Class III/IV + INMETRO pass-through and BGMP manufacturing-site audit as pass-through lines stay on that hub — this intercept is not a second price list. Trial IOR: importer of record for clinical trial devices.
BRH stack vs freelance advice
- Who is the detentor / BRH? ANVISA names a Brazilian legal entity on the registration. A consultant who helps you appoint is not the detentor.
- Who owns Portuguese sworn pages where required? Inside the published all-in card on the hub — do not compare a dossier-only sticker to USD 7,500 all-in.
- Who owns BGMP / INMETRO pass-through? Published outside the flat fee on the holder hub — not a freelancer rate we invent here.
- Who owns CEP + ANVISA when the SKU is FIH? CRO execution on clinical-trials-brazil — not a classification PDF.
- Who owns inspection-ready ops? ISO 14155 monitoring and TMF/ISF — bioaccess® when you hire the CRO stack.
Colombia line (cluster hygiene)
Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®. Brazil ANVISA success does not reopen Colombia FIH from this page.
How sponsors mis-buy “ANVISA RA”
Brazil searches collapse BRH support, clinical RDC 837/2023 coaching, and INMETRO pass-through into one “RA consultant” phrase. Separate them. FIH / early feasibility lives on clinical-trials-brazil. Commercial detentor lives on ANVISA holder / IOR. Homologation and BGMP pass-through stay on the holder hub terms — not invented here. bioaccess® owns the operator conversation end-to-end when you hire the stack. Always bioaccess®.
Frequently asked questions
Is an ANVISA regulatory consultant a CRO?
No. Advice is not CEP + ANVISA start-up, and it is not BRH. bioaccess® sells the operator stack for both trial and commercial SKUs when that is the real job.
Does bioaccess® replace freelancers?
We do not name freelancers. We intercept Brazil RA consultant / ANVISA regulatory consultant intent and convert to contact, market-access, clinical-trials-brazil, or the BRH holder page.
Is BRH support the same as the all-in holder card?
No. “Help with BRH” is not own-entity detentor. See the Brazil holder sibling and the LATAM hub for the locked USD 7,500/year all-in card.
Rates?
No invented Pure Global or freelancer rates. Locked public card only when a card is mentioned.
Siblings?
Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Colombia RA Consultant / INVIMA
Next step
Brazil RA / ANVISA search → operator path: contact bioaccess® · market-access · clinical-trials-brazil · ANVISA holder / IOR · siblings Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Colombia RA Consultant / INVIMA.
Julio G. Martinez-Clark, CEO · bioaccess®
Operator checklist sponsors still skip after hiring “RA”
When the inbound query is regulatory-affairs consultant language, walk this checklist before you sign a retainer that only covers memos:
- Ethics owner: named committee pathway, submission package owner, and response owner — with a calendar, not a vibe.
- Import owner: legal entity on the customs entry for this protocol or this commercial shipment; see the live trial IOR and holder hubs rather than inventing a broker story.
- Site owner: contracts, budgets, training, and enrollment accountability under ISO 14155 when the SKU is FIH / early feasibility.
- Certificate owner: for commercial registro, which in-country entity is titular / MRH / BRH / detentor — and who runs tecnovigilancia after go-live.
- Inspection owner: TMF/ISF discipline, monitoring, and CAPA. A classification PDF does not answer an inspector.
- Country-select owner: apply the Colombia public line before anyone sells you a new INVIMA FIH from an RA search; keep Mexico, Brazil, Panama, Chile, and El Salvador on the recommended FIH conversation where the live hubs support it.
- Commercial card owner: if the SKU is already-cleared devices, use the locked public LATAM Launch Subscription on market-access — USD 7,500/year all-in for the first device family — and do not invent freelancer comparables on this page.
- Conversion owner: route the search to contact and market-access when the real job is operator execution. Always bioaccess®.
bioaccess® is a DBA of IMH ASSETS CORP. Julio G. Martinez-Clark, Co-Founder and CEO. The founder podcast is Global Trial Accelerators™. This intercept is public content only. It is not leftover-site hospital FIH copy, not insurance underwriting, and not a Magical BTK page. Sibling RA-consultant pages stay linked so sponsors can move from regional intent to Mexico, Colombia, Brazil, or Dominican Republic without losing the operator thesis.
Repeat the thesis in plain language for searchers who skim: hiring a freelance RA consultant is not the same as running FIH, early feasibility, or registration execution. You still need the ethics calendar, IOR/import, site network, and inspection-ready operations. bioaccess® owns that LATAM stack as FIH CRO plus local RA/IOR operator. Convert via contact and market-access. No invented rates. No named freelancers. No PHI. Always write bioaccess® with the registered mark.